Compass Pathways SEC Filings

Type
Report
Date
4Insidertransaktion3/13/2026
4Insidertransaktion3/13/2026
4Insidertransaktion3/3/2026
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben2/19/2026
424B5424B5-Formular2/19/2026
SCHEDULE 13D/ASCHEDULE 13D/A-Formular2/17/2026
424B5424B5-Formular2/17/2026
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben2/17/2026
4Insidertransaktion2/3/2026
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben1/7/2026
SCHEDULE 13G/ASCHEDULE 13G/A-Formular11/14/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular11/14/2025
10-QQuartalsbericht11/4/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben11/4/2025
33-Formular10/31/2025
4Insidertransaktion10/31/2025
SCHEDULE 13D/ASCHEDULE 13D/A-Formular10/29/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben10/29/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular8/14/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular8/14/2025
SCHEDULE 13GSCHEDULE 13G-Formular8/14/2025
4Insidertransaktion8/4/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben7/31/2025
10-QQuartalsbericht7/31/2025
4Insidertransaktion7/30/2025
33-Formular7/30/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben7/29/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben6/23/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben6/13/2025
4Insidertransaktion6/13/2025
4Insidertransaktion6/13/2025
4Insidertransaktion6/13/2025
4Insidertransaktion6/13/2025
4Insidertransaktion6/13/2025
4Insidertransaktion6/13/2025
4Insidertransaktion6/13/2025
4Insidertransaktion6/13/2025
SCHEDULE 13GSCHEDULE 13G-Formular5/15/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular5/15/2025
424B5424B5-Formular5/8/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben5/8/2025
10-QQuartalsbericht5/8/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular5/7/2025
EFFECTEFFECT-Formular5/7/2025
CORRESPCORRESP-Formular5/5/2025
ARSARS-Formular4/28/2025
DEF 14ADEF 14A-Formular4/28/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben4/16/2025
PRE 14APRE 14A-Formular4/16/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular4/15/2025
4Insidertransaktion3/13/2025
4Insidertransaktion3/13/2025
4Insidertransaktion3/13/2025
SCHEDULE 13D/ASCHEDULE 13D/A-Formular3/5/2025
4Insidertransaktion3/4/2025
S-8S-8-Formular2/27/2025
S-3S-3-Formular2/27/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben2/27/2025
10-KJahresbericht2/27/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular2/14/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular2/13/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular2/6/2025
4Insidertransaktion2/5/2025
SCHEDULE 13GSCHEDULE 13G-Formular1/17/2025
424B5424B5-Formular1/10/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben1/10/2025
SC 13G/ABeneficial ownership report11/14/2024
SC 13G/ABeneficial ownership report11/14/2024
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben10/31/2024
10-QQuartalsbericht10/31/2024
4Insidertransaktion10/25/2024
4Insidertransaktion10/25/2024
424B5424B5-Formular10/18/2024
EFFECTEFFECT-Formular10/17/2024
CORRESPCORRESP-Formular10/15/2024
UPLOADUPLOAD-Formular10/11/2024
S-3S-3-Formular10/7/2024
4Insidertransaktion9/27/2024
SC 13D/ASC 13D/A-Formular9/27/2024
4Insidertransaktion9/4/2024
33-Formular9/4/2024
4Insidertransaktion8/5/2024
4Insidertransaktion8/5/2024
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben8/1/2024
10-QQuartalsbericht8/1/2024
4Insidertransaktion5/22/2024
4Insidertransaktion5/22/2024
F-6EFF-6EF-Formular5/15/2024
4Insidertransaktion5/13/2024
4Insidertransaktion5/13/2024
4Insidertransaktion5/13/2024
4Insidertransaktion5/13/2024
4Insidertransaktion5/13/2024
4Insidertransaktion5/13/2024
4Insidertransaktion5/13/2024
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben5/9/2024
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben5/8/2024
10-QQuartalsbericht5/8/2024
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben5/8/2024
4Insidertransaktion5/6/2024

Compass Pathways Documents 2026

This page contains all official documents and SEC filings for Compass Pathways stock (CMPS, ISIN: US20451W1018). This includes annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transactions (Form 4). Currently 100 documents are available. Data is updated regularly to provide investors with a complete overview of Compass Pathways's regulatory filings.

Compass Pathways Stock analysis

Compass Pathways Compass Pathways PLC is a leading company specializing in the development of groundbreaking therapies for the treatment of mental illnesses. The company was founded in 2016 and is headquartered in London. Its goal is to revolutionize the treatment of depression and other mental illnesses. The business model of Compass Pathways is based on researching psychedelics as a potential treatment for patients suffering from severe depression and anxiety disorders. The company uses innovative approaches to precisely study the effects of psychedelics on the human brain and develop new therapy concepts and products from that. An important area of Compass Pathways is clinical research. The company collaborates closely with leading research institutions to understand the impacts of psychedelics on the human brain. The research results are then used to develop innovative methods for therapeutic use of psychedelics. Another important area of Compass Pathways is the development of therapeutic products. The company has developed a patented process for producing psilocybin, a substance found in hallucinogenic mushrooms. This process achieves a very high purity of the substance, enabling precise dosing and better control of its effects. The flagship product of Compass Pathways is COMP360, a medication based on psilocybin that is being developed for the treatment of depression. The medication is currently in clinical Phase 2 trials, showing promising results. If COMP360 receives approval, it has the potential to drastically change the way we treat depression. Compass Pathways is also active in other areas. The company conducts a range of research projects related to various psychedelic substances, including LSD and other hallucinogens. Another important area of Compass Pathways is training therapists and other professionals in the use of psychedelic substances. The company offers relevant courses to promote understanding of the therapeutic use of psychedelics and enable their safe and effective application for patient treatment. Overall, Compass Pathways is a company focused on the development of groundbreaking therapies for mental illnesses. Through combining cutting-edge research, innovative products, and professional education, the company has the potential to revolutionize the way we treat mental illnesses.